Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Berapa harga saham Eiger BioPharmaceuticals hari ini?▼
Harga saat ini dari 72C1.F adalah €0.21 EUR — naik sebesar +0% dalam 24 jam terakhir. Pantau kinerja harga saham Eiger BioPharmaceuticals lebih dekat di grafik.
Apa simbol saham Eiger BioPharmaceuticals?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Eiger BioPharmaceuticals diperdagangkan dengan simbol 72C1.F.
Berapa pendapatan Eiger BioPharmaceuticals tahun lalu?▼
Pendapatan Eiger BioPharmaceuticals tahun lalu berjumlah 12.93M EUR.
Berapa pendapatan bersih Eiger BioPharmaceuticals tahun lalu?▼
Pendapatan bersih 72C1.F untuk tahun lalu adalah -92.41M EUR.
Berapa jumlah karyawan Eiger BioPharmaceuticals?▼
Per April 29, 2026, perusahaan memiliki 51 karyawan.
Eiger BioPharmaceuticals berada di sektor apa?▼
Eiger BioPharmaceuticals beroperasi di sektor Kesehatan & Kebugaran.